recombinant human fibulin 5  (R&D Systems)

Journal: Aging Cell

Article Title: Integrin‐Binding Matricellular Protein Fibulin‐5 Maintains Epidermal Stem Cell Heterogeneity During Skin Aging

doi: 10.1111/acel.70483

Figure Lengend Snippet: Impact of fibulin‐5 deficiency on the skin aging process. (A) Schematic representation of the interfollicular epidermis of mouse tail skin. Slow‐cycling epidermal stem cells (SCs) produce the K10 + interscale lineage (orange), and fast‐cycling epidermal SCs produce the K36 + scale lineage (blue). (B, C) Immunostaining of fibulin‐5 (green) in sections of mouse tail skin from 2‐month‐old versus 30‐month‐old C57BL/6J mice and quantification (C). The white dashed line represents the epidermal–dermal boundary. Scale bars: 50 μm. (D, E) Immunostaining of fibulin‐5 (green) in sections of mouse tail skin from 3‐month‐old Fbln5 WT versus KO mice and quantification (E). The white dashed line represents the epidermal–dermal boundary and hair follicles. Scale bars: 50 μm. (F) Images of 12‐month‐old Fbln5 WT and KO mice. (G) The body weights of 12‐month‐old Fbln5 WT and KO mice. (H–K) Hematoxylin and eosin staining of sagittal sections of the skin of 3‐ and 12‐month‐old Fbln5 WT versus KO mice and quantification (I, K). Scale bars: 150 μm. Epidermal thickness was measured in interscale and scale regions. (L–O) Whole‐mount staining of BrdU (green, a proliferation marker) and Hoechst (blue) in 3‐ and 12‐month‐old Fbln5 WT versus KO mice and quantification (M, O). Scale bars: 200 μm. (P–U) Whole‐mount staining of K10 (green, interscale lineage), K36 (red, scale lineage), and Hoechst (blue) in 2‐month‐old versus 30‐month‐old C57BL/6J mice and 3‐ and 12‐month‐old Fbln5 WT versus KO mice and quantification (Q, S, U). Scale bars: 200 μm. All data are presented as the mean ± SD. Each dot represents one mouse. Statistical significance is assessed using a two‐tailed unpaired t ‐test (C, E, G, I, K, M, O, Q, S, U). *, p < 0.05; **, p < 0.01; ns, not significant.

Article Snippet: For the fibulin‐5 coating assay, the 12‐well plates were coated overnight at 4°C with collagen type IV (50 μg/mL in PBS) either alone or with 90 ng/mL recombinant human fibulin‐5 (R&D Systems) in PBS.

Techniques: Immunostaining, Staining, Marker, Two Tailed Test

Journal: Aging Cell

Article Title: Integrin‐Binding Matricellular Protein Fibulin‐5 Maintains Epidermal Stem Cell Heterogeneity During Skin Aging

doi: 10.1111/acel.70483

Figure Lengend Snippet: Changes in integrin and extracellular matrix expression due to the loss of fibulin‐5. (A) The heatmap shows changes in integrins and ECM proteins in 12‐month‐old Fbln5 WT and KO epidermal stem cells. Genes with a ≥ 2‐fold change are used for analysis. (B) Schematic representation of the epidermal–dermal junction and its associated proteins. (C–V) Immunostaining and quantification of the indicated proteins: Collagen XVII (C–F; green), integrin β1 (G–J; green), integrin α6 (K–N; red) integrin β3 (O–R; green), nectin‐3 (S–V; green), K5 (S–V; gray), and K36 (S–V; red, scale lineage). The white dashed lines represent the epidermal–dermal boundary. Scale bars: 50 μm. All data are presented as the mean ± SD. Each dot represents one mouse. Statistical significance is assessed using a two‐tailed unpaired t ‐test (D, F, H, J, N, P, R, T, V) or Mann–Whitney U test (L). *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant. The schematic in panel B is created with BioRender.com .

Article Snippet: For the fibulin‐5 coating assay, the 12‐well plates were coated overnight at 4°C with collagen type IV (50 μg/mL in PBS) either alone or with 90 ng/mL recombinant human fibulin‐5 (R&D Systems) in PBS.

Techniques: Expressing, Immunostaining, Two Tailed Test, MANN-WHITNEY

Journal: Aging Cell

Article Title: Integrin‐Binding Matricellular Protein Fibulin‐5 Maintains Epidermal Stem Cell Heterogeneity During Skin Aging

doi: 10.1111/acel.70483

Figure Lengend Snippet: Extracellular fibulin‐5 enhances YAP activity and fast‐cycling stem cell‐associated gene expression in human keratinocytes. (A–H) Immunostaining of YAP (A, green), SLC1A3 (C, red), Ki‐67 (E, gray), and ASS1 (G, green) in human keratinocytes and quantification (B, D, F, H). Cells are seeded at 150,000, 50,000, and 25,000 cells per well in 12‐well plates and cultured for 48 h before analysis. Scale bars: 50 μm. (I, J) Immunostaining of YAP in primary human keratinocytes and quantification (J). Cells are seeded at 50,000 cells per well in 12‐well plates and cultured for 24 h and then treated with verteporfin or vehicle control for 8 h. Nuclear YAP (%) was calculated as the proportion of cells with nuclear YAP localization among all Hoechst + nuclei. Scale bars: 50 μm. (K–M) RT‐qPCR analysis of CTGF , SLC1A3 , and ASS1 following 8 h of verteporfin treatment. (N, O) Immunostaining of YAP in primary human keratinocytes and quantification (O). Cells are seeded at 300,000 cells per well on collagen IV–coated plates with or without recombinant human fibulin‐5 and cultured to ~80% confluence. The medium is then replaced, and cells are analyzed 8 h later. Scale bars: 50 μm. (P–R) RT‐qPCR analysis of CTGF , SLC1A3 , and ASS1 following culture on plates coated with collagen IV ± fibulin‐5. All data are presented as the mean ± SD. Each dot represents one independent biological replicate. Statistical significance is assessed using a two‐tailed unpaired t ‐test (K, L, P, Q, R), Welch's t ‐test (J, M, O), or one‐way ANOVA (B, D, F, H). *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant.

Article Snippet: For the fibulin‐5 coating assay, the 12‐well plates were coated overnight at 4°C with collagen type IV (50 μg/mL in PBS) either alone or with 90 ng/mL recombinant human fibulin‐5 (R&D Systems) in PBS.

Techniques: Activity Assay, Gene Expression, Immunostaining, Cell Culture, Control, Quantitative RT-PCR, Recombinant, Two Tailed Test

Journal: Aging Cell

Article Title: Integrin‐Binding Matricellular Protein Fibulin‐5 Maintains Epidermal Stem Cell Heterogeneity During Skin Aging

doi: 10.1111/acel.70483

Figure Lengend Snippet: Proposed model of cellular and molecular alterations associated with fibulin‐5 deficiency during skin aging. In young skin, slow‐cycling and fast‐cycling epidermal stem cells (SCs) are spatially compartmentalized and give rise to their respective lineages. During aging, decreased fibulin‐5 expression is associated with altered integrin and extracellular matrix (ECM) protein expression, potentially affecting intracellular signaling through fibulin‐5–integrin interactions. Reduced YAP activity is associated with a decrease in the fast‐cycling epidermal stem cell compartment in aged skin and human keratinocytes. The schematic is created with BioRender.com .

Article Snippet: For the fibulin‐5 coating assay, the 12‐well plates were coated overnight at 4°C with collagen type IV (50 μg/mL in PBS) either alone or with 90 ng/mL recombinant human fibulin‐5 (R&D Systems) in PBS.

Techniques: Expressing, Activity Assay

Journal: bioRxiv

Article Title: Satellite Glial Cells Control Sensory Neuron Excitability via the Release of Fibulin-2

doi: 10.64898/2026.02.13.705760

Figure Lengend Snippet: A. Sample traces of action potentials (APs) recorded from Control and rFibulin-2-treated DRG neurons. APs were evoked by ramp current injection (0.15 pA/ms) via recording pipettes. Traces within shaded areas were used to calculate input resistance at hyperpolarization (blue, summarized in O ) and depolarization (red, summarized in P ) states. B-F . rFibulin-2 treatment decreased excitability of DRG neurons, as shown by reduced number of APs ( B ), and increases in the initial inter-AP interval ( C ), AP rheobase ( D ), normalized rheobase ( E ), and rheobase charge transfer ( F ). Number of cells tested from 3 independent experiments: control n = 10; rFibulin-2: n = 12. G-K . rFibulin-2 did not affect multiple other AP parameters, including AP threshold ( G ), maximal rise rate ( H ), amplitude ( I ), duration ( J ) and fast afterhyperpolarization (fAHP) ( K ). Number of cells tested from 3 independent experiments: control n = 10; rFibulin-2: n = 12. L-N . The recorded cells have comparable size ( L ), membrane capacitance ( M ), and resting membrane potential (RMP) ( N ). Number of cells tested from 3 independent experiments: control n = 10–15; rFibulin-2: n = 12–13. O-P . rFibulin-2 decreased input resistance of DRG neurons at depolarization state ( P ). However, it did not affect the input resistance at hyperpolarization state ( O ). Number of cells tested from 3 independent experiments: control n = 8–9; rFibulin-2: n = 12. T-test; * P < 0.05; ** P < 0.01; ns, not significant.

Article Snippet: For rFibulin-2 treatment, the cells were exposed to 2 μg/ml rFibulin-2 protein (R&D System Catalog # 9559-FB-050) or MQ water as a control at the time of seeding, and they were incubated for an additional 24 hours.

Techniques: Control, Injection, Membrane

Journal: bioRxiv

Article Title: Satellite Glial Cells Control Sensory Neuron Excitability via the Release of Fibulin-2

doi: 10.64898/2026.02.13.705760

Figure Lengend Snippet: A . Voltage protocols for measurement of different types of K + currents: total ( I Total ), K-type ( I K ) and A-type ( I A ) K + currents. B . Sample traces of voltage-dependent K + currents I total (left), I K (middle) and I A (right) evoked by the protocols in ( A ) from Control (upper panel) and rFibulin-2 treated DRG cells (lower panel). C . rFibulin-2 increases voltage-dependent K + currents I Total (left), I K (middle) and I A (right) in DRG cells. Insert bar graphs are K + currents at membrane potential of -10 mV (around voltage threshold level), indicating that rFibulin-2 decreases excitability mainly mediated by enhancement of I A conductance, which reduces input resistance. Number of cells tested from 3 independent experiments: control n = 10; rFibulin-2: n = 8. D . Phrixotoxin-1 (PaTx1) was used to isolate Kv4 current evoked by voltage ramp (-100 to +20 mV, 100 mV/s). Sample traces of ramp-evoked K + currents before (a) and during (b) application of PaTx1, and the PaTx1-sensitive current (c, c = a - b). Currents were normalized to membrane capacitance for better comparison. E . I-V curves were constructed from the ramp-evoked Kv4 current (mean current value over 0.1 mV intervals from averages of five trials for each cell to approximate quasi-steady-state current). Note PaTx1 significantly increases the Kv4 current when the membrane potentials are depolarized to positive values greater than -25 mV. Number of cells tested from 3 independent experiments: control n = 6; rFibulin-2: n = 6; T-test; * P < 0.05; ** P < 0.01. F . Representative western blot of control and Fibulin-2 KO DRG lysate analyzed for Fibulin-2 and Kv4.2. GAPDH is used as a loading control. G . Quantification of Kv4.2 expression in control and Fibulin-2 KO mice. n=3 WT and n=3 Fibulin-2 KO mice. T-test; ** P < 0.01. H . Representative western blot of control and Fibulin-2 KO DRG lysate analyzed for Fibulin-2 and Kv4.3. GAPDH is used as a loading control. I . Quantification of Kv4.3 expression in control and Fibulin-2 KO mice. n=3 WT and n=3 Fibulin-2 KO mice. T-test; *** P < 0.001 J . Fibulin-2 KO mice show hypersensitivity to mechanical stimuli compared to controls, measured by the Von Frey Test. 12 WT and 8 Fibulin-2 KO mice were used. Two-Way Anova. ∗p < 0.05, ∗∗p < 0.01, ***p<0.001. K . Fibulin-2 KO mice exhibit hypersensitivity to heat stimuli compared to controls, measured by the Hot-Plate test. 12 WT and 8 Fibulin-2 KO mice were used. Two-Way Anova. ∗p < 0.05, ∗∗p < 0.01, ***p<0.001. L . Fibulin-2 KO mice exhibit hypersensitivity to cold stimuli compared to controls, measured by the Cold-Plate test. 12 WT and 8 Fibulin-2 KO mice were used. Two-Way Anova. ∗p < 0.05, ∗∗p < 0.01, ***p<0.001. M . Representative immunofluorescence images of the hindpaw of control and Fibulin-2 KO mice immunostained for PGP9.5 (white) and DAPI (blue). Three sections from n=3 mouse per group were used. N . Quantification of intraepidermal nerve fiber density (IENFD). n=3 mice per genotype. T-test, ns- non-significant

Article Snippet: For rFibulin-2 treatment, the cells were exposed to 2 μg/ml rFibulin-2 protein (R&D System Catalog # 9559-FB-050) or MQ water as a control at the time of seeding, and they were incubated for an additional 24 hours.

Techniques: Control, Membrane, Comparison, Construct, Western Blot, Expressing, Hot Plate Test, Immunofluorescence

Journal: Genes to Cells

Article Title: Alternative Splicing of FBLN2 Generates a Prometastatic Extracellular Matrix in Gastrointestinal Cancers by Determining N‐Glycosylation of Fibulin 2

doi: 10.1111/gtc.70027

Figure Lengend Snippet: Variant 2 is the major FBLN2 splice variant expressed in the fibroblasts of gastrointestinal cancers. (A) Schematic representation of the human FBLN2 gene. Exon (E) 9 (magenta) is included or excluded in variant 1 (v1) or variant 2 (v2) mRNAs, respectively. (B) Difference in splicing of FBLN2 exon 9 between normal (N) and primary tumor (T) tissue for 16 types of cancer in the TCGASpliceSeq database. Cancer type abbreviations are as in Table . PSI, percent spliced‐in. The values at the bottom indicate the number of tumor (T) and normal (N) tissues examined. (C, D) Box plots for PSI values of FBLN2 exon 9 determined from RNA‐seq data for normal (N), primary tumor (T), or metastatic liver tumor (M) tissue for four selected cancer types in TCGA (C) or for CRC in GSE50760 (D). (E) RT‐qPCR analysis of the expression of FBLN2 v1 and v2 in normal and primary tumor tissue isolated from CRC patients. Data are means ± SEM ( n = 7 patients). (F) Expression profiles for FBLN2 in CRC tissue determined by scRNA‐seq analysis ( GSE178341 ). The color intensity in the left plot represents the abundance of FBLN2 mRNA as shown by Log (TP10K + 1). TP10K + 1 indicates transcripts per 10 thousand plus one reads. The colors in the right plot correspond to cell identities. ILC, innate lymphoid cell; NK, natural killer. (G) Violin plots for the expression level of FBLN2 in five stromal cell types determined by scRNA‐seq analysis as in (F). (H) Representative immunohistochemical staining of FBLN2 in a tissue section containing normal epithelium isolated from a CRC patient. Boxed regions in the left image are shown at higher magnification in the middle and right images. BV, blood vessel; EL, epithelial layer; LP, lamina propria; MM, muscularis mucosae. Scale bars, 300 μm (left) and 100 μm (middle and right). (I) RT‐qPCR analysis of FBLN2 v1 and v2 expression in primary fibroblasts isolated from normal (N) or primary tumor (T) tissue of gastrointestinal cancer patients. Data are means ± SEM ( n = 6 patients). * p < 0.05, ** p < 0.01, *** p < 0.001, n.s. (not significant) by the Wilcoxon rank sum test followed by Benjamini–Hochberg correction for multiple testing (B, C), by one‐way analysis of variance (ANOVA) followed by Tukey's post hoc test (D), or by the paired t test (E, I).

Article Snippet: For the transwell migration assay, the lower side of the filter membrane (diameter of 6.5 mm, pore size of 8 μm; 3422, Corning) was treated with FN1 (F0895, Sigma‐Aldrich), recombinant FBLN2 v2 (9559‐FB‐050, R&D Systems), or BSA (017‐23294, Fujifilm Wako) for 10 min and then allowed to dry for 30 min. HCT 116 cells were suspended in serum‐free McCoy's 5A medium, seeded at a density of 5 × 10 4 per membrane, and allowed to migrate for 24 or 48 h at 37°C and under 5% CO 2 .

Techniques: Variant Assay, RNA Sequencing, Quantitative RT-PCR, Expressing, Isolation, Immunohistochemical staining, Staining

Journal: Genes to Cells

Article Title: Alternative Splicing of FBLN2 Generates a Prometastatic Extracellular Matrix in Gastrointestinal Cancers by Determining N‐Glycosylation of Fibulin 2

doi: 10.1111/gtc.70027

Figure Lengend Snippet: Splicing of FBLN2 exon 9 determines N‐glycosylation of FBLN2 protein. (A, B) 24N‐T fibroblasts infected (or not) with a recombinant lentivirus encoding FBLN2‐3 × FLAG v1 or v2 were subjected to immunoblot analysis with antibodies to FLAG (A) or to RT‐qPCR analysis of FBLN2 mRNA (B). FN1 expression was analyzed as a loading control in (A). Data in (B) are means ± SEM ( n = 3 independent experiments). (C, D) 24N‐T fibroblasts engineered as in (A) were subjected to immunoprecipitation (IP) with antibodies to FLAG, and the resulting precipitates were subjected to SDS‐PAGE and staining with Oriole fluorescent dye (C) or to immunoblot analysis (IB) of HSPA5 (D). The arrowhead in (C) indicates the position of HSPA5 coprecipitated with FBLN2‐3 × FLAG v2. (E) FBLN2‐3 × FLAG v1 or v2 prepared from culture supernatants of 24N‐T fibroblasts engineered as in (A) was treated (or not) with the indicated glycosidases and then subjected to immunoblot analysis of FLAG. (F) HEK293T cells expressing FBLN2‐3 × FLAG v1 or v2 were treated with various concentrations of tunicamycin, after which medium (culture supernatant) and cell lysate (cells attached to culture dish) were prepared and subjected to immunoblot analysis of FLAG. Oriole staining of the SDS‐PAGE gel and immunoblot analysis of β‐actin were performed as loading controls for medium and cell lysate fractions, respectively. (G) Schematic representation of human FBLN2 v1 and v2 proteins. Triangles indicate the positions of putative N‐glycosylation sites. The positions of cbEGF‐like domains and anaphylatoxin (AT) modules are also shown. (H) Immunoblot analysis of FLAG for HEK293T cells expressing WT or mutant versions of FBLN2‐3 × FLAG v1 or v2 (upper panel). Cell lysates were fractionated by SDS‐PAGE in the presence (ConA gel) or absence (Standard gel) of concanavalin A. Schematic representations of N‐glycosylation sites for v1 (bottom left) and v2 (bottom right) are also shown. (I) FBLN2‐3 × FLAG v1 or v2 immunoprecipitated from 24N‐T fibroblasts engineered as in (A) was subjected to SDS‐PAGE and stained for glycoproteins (upper) or total proteins (lower). The different mobility of protein size markers between glycoprotein gel (upper) and total protein gel (lower) is likely due to the use of distinct molecular weight standards, in which the 180 kDa marker band is glycosylated. (J) Quantification of signal intensity as in (I). Data are means ± SEM ( n = 4 independent experiments). * p < 0.05, *** p < 0.001 by Student's t test (B, J).

Article Snippet: For the transwell migration assay, the lower side of the filter membrane (diameter of 6.5 mm, pore size of 8 μm; 3422, Corning) was treated with FN1 (F0895, Sigma‐Aldrich), recombinant FBLN2 v2 (9559‐FB‐050, R&D Systems), or BSA (017‐23294, Fujifilm Wako) for 10 min and then allowed to dry for 30 min. HCT 116 cells were suspended in serum‐free McCoy's 5A medium, seeded at a density of 5 × 10 4 per membrane, and allowed to migrate for 24 or 48 h at 37°C and under 5% CO 2 .

Techniques: Glycoproteomics, Infection, Recombinant, Western Blot, Quantitative RT-PCR, Expressing, Control, Immunoprecipitation, SDS Page, Staining, Mutagenesis, Molecular Weight, Marker

Journal: Genes to Cells

Article Title: Alternative Splicing of FBLN2 Generates a Prometastatic Extracellular Matrix in Gastrointestinal Cancers by Determining N‐Glycosylation of Fibulin 2

doi: 10.1111/gtc.70027

Figure Lengend Snippet: FBLN2 v2 is less stable and secreted to a lesser extent compared with v1. (A–C) 24N‐T fibroblasts infected with a recombinant retrovirus encoding FBLN2‐3 × FLAG v1 or v2 were subjected to RT‐qPCR analysis of FBLN2 mRNA (A) or to cellular fractionation followed by immunoblot analysis of FLAG (B, C). Quantitative data are means ± SEM ( n = 4 independent experiments). (D–G) 24N‐T fibroblasts engineered as in (A) were incubated with cycloheximide (100 μg/mL) for the indicated times (D) or with various concentrations of MG132 for 6 h (F), after which cell lysates were subjected to immunoblot analysis of FLAG or β‐actin (loading control). Arrowheads indicate the positions of the intracellular forms of FBLN2. Signal intensity for the intracellular forms of v1 and v2 was also determined (E, G), with the data presented as means ± SEM ( n = 4 independent experiments). ** p < 0.01, *** p < 0.001, n.s. by Student's t test (A, C), by repeated measures ANOVA (E), or by two‐way ANOVA (G).

Article Snippet: For the transwell migration assay, the lower side of the filter membrane (diameter of 6.5 mm, pore size of 8 μm; 3422, Corning) was treated with FN1 (F0895, Sigma‐Aldrich), recombinant FBLN2 v2 (9559‐FB‐050, R&D Systems), or BSA (017‐23294, Fujifilm Wako) for 10 min and then allowed to dry for 30 min. HCT 116 cells were suspended in serum‐free McCoy's 5A medium, seeded at a density of 5 × 10 4 per membrane, and allowed to migrate for 24 or 48 h at 37°C and under 5% CO 2 .

Techniques: Infection, Recombinant, Quantitative RT-PCR, Cell Fractionation, Western Blot, Incubation, Control

Journal: Genes to Cells

Article Title: Alternative Splicing of FBLN2 Generates a Prometastatic Extracellular Matrix in Gastrointestinal Cancers by Determining N‐Glycosylation of Fibulin 2

doi: 10.1111/gtc.70027

Figure Lengend Snippet: The ECM environment of CRC tissue exhibits low FBLN2 and high FN1 abundance. (A) Lysates prepared from normal (N) or primary tumor (T) tissue of CRC patients were subjected to immunoblot analysis of FBLN2 with the indicated antibodies. The gel was also stained with Oriole fluorescent dye to allow adjustment for protein loading. (B) Quantification of signal intensity as in (A). Data are means ± SEM ( n = 9 patients). (C) Representative immunohistochemical staining of extracellular FBLN2 (HPA001934) in a section containing primary tumor (T) and adjacent normal (N) tissue isolated from a CRC patient. The boxed regions in the upper image are shown at higher magnification in the lower images. FBLN2 signals in the lamina propria (LP) are indicated by arrowheads in the lower left image. BV, blood vessel; EL, epithelial layer; MM, muscularis mucosae. Scale bars, 1 mm (upper) and 100 μm (lower). (D) Representative immunofluorescence analysis of FBLN2 and FN1 in 21N‐T (upper) or 24N‐T (lower) fibroblasts isolated from rectal cancer or gastric cancer patients, respectively. DNA was stained with 4′,6‐diamidino‐2‐phenylindole (DAPI). Scale bars, 50 μm. (E) Box plots for FN1 mRNA level based on transcripts per million (TPM) in normal (N) and primary tumor (T) tissue for COADREAD in TCGA. (F) Immunoblot analysis of FN1 in lysates prepared from normal (N) and primary tumor (T) tissue of CRC patients. The gel was stained for total proteins with Oriole fluorescent dye. (G) Box plots for FN1 mRNA level based on fragments per kilobase of exon per million mapped reads (FPKM) in normal (N), primary CRC tumor (T), and metastatic liver tumor (M) tissue determined by RNA‐seq analysis ( GSE50760 ) as in Figure . * p < 0.05, ** p < 0.01, *** p < 0.001, n.s. by the paired t test (B), Wilcoxon rank sum test (E) or by one‐way ANOVA followed by Tukey's post hoc test (G).

Article Snippet: For the transwell migration assay, the lower side of the filter membrane (diameter of 6.5 mm, pore size of 8 μm; 3422, Corning) was treated with FN1 (F0895, Sigma‐Aldrich), recombinant FBLN2 v2 (9559‐FB‐050, R&D Systems), or BSA (017‐23294, Fujifilm Wako) for 10 min and then allowed to dry for 30 min. HCT 116 cells were suspended in serum‐free McCoy's 5A medium, seeded at a density of 5 × 10 4 per membrane, and allowed to migrate for 24 or 48 h at 37°C and under 5% CO 2 .

Techniques: Western Blot, Staining, Immunohistochemical staining, Isolation, Immunofluorescence, RNA Sequencing

Journal: Genes to Cells

Article Title: Alternative Splicing of FBLN2 Generates a Prometastatic Extracellular Matrix in Gastrointestinal Cancers by Determining N‐Glycosylation of Fibulin 2

doi: 10.1111/gtc.70027

Figure Lengend Snippet: FBLN2 suppresses the adhesion and migration of CRC cells. (A) Representative results for a transwell migration assay in which HCT 116 cells were seeded on a transwell insert coated (or not) with FN1 (20 μg/mL) or FBLN2 v2 (20 μg/mL) and were then allowed to migrate for 48 h. (B) Quantification of the area of migrated cells as in (A). Data are means ± SEM ( n = 3 independent experiments). (C) Representative results for a transwell migration assay in which HCT 116 cells were seeded on a transwell insert coated (or not) with FN1 (20 μg/mL) and various concentrations of FBLN2 v2 or BSA and were then allowed to migrate for 24 h. (D) Quantification of the area of migrated cells as in (C). Data are means ± SEM ( n = 4 independent experiments). (E) Representative results for a cell adhesion assay in which HCT 116 cells were seeded in low‐attachment dishes coated (or not) with FN1 (2 μg/mL) and various concentrations of FBLN2 v2 or BSA. (F) Quantification of attached cells as in (E). (G) Model for the role of alternative splicing of FBLN2 exon 9 in the remodeling of ECM. Data are means ± SEM ( n = 3 independent experiments). * p < 0.05, ** p < 0.01, *** p < 0.001, n.s. by one‐way ANOVA followed by Tukey's post hoc test (B, D, F). Scale bars, 200 μm (A, C) and 100 μm (E).

Article Snippet: For the transwell migration assay, the lower side of the filter membrane (diameter of 6.5 mm, pore size of 8 μm; 3422, Corning) was treated with FN1 (F0895, Sigma‐Aldrich), recombinant FBLN2 v2 (9559‐FB‐050, R&D Systems), or BSA (017‐23294, Fujifilm Wako) for 10 min and then allowed to dry for 30 min. HCT 116 cells were suspended in serum‐free McCoy's 5A medium, seeded at a density of 5 × 10 4 per membrane, and allowed to migrate for 24 or 48 h at 37°C and under 5% CO 2 .

Techniques: Migration, Transwell Migration Assay, Cell Adhesion Assay, Alternative Splicing